Susquehanna Fundamental Investments’s Rocket Pharmaceuticals RCKT Stock Holding History

Susquehanna Fundamental Investments’s Portfolio RCKT Stock Details RCKT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-50,970	Closed	-$179K	–	662
2025 Q4	$179K	Sell	50,970 -68,643	-57%	-$235K	0.01%	517
2025 Q3	$390K	Sell	119,613 -85,765	-42%	-$270K	0.02%	456
2025 Q2	$503K	Hold	205,378	–	–	0.01%	547
2025 Q1	$1.37M	Buy	+205,378	New	+$2.03M	0.02%	614
2021 Q2	–	Sell	-25,900	Closed	-$1.15M	–	1755
2021 Q1	$1.15M	Buy	+25,900	New	+$1.42M	0.02%	833

Other funds holding RCKT

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Maverick Capital Dallas, Texas $11.3B AUM 76.6% 1-Year Est. Return

Newtyn Management New York $801M AUM 23.14% 1-Year Est. Return

Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Susquehanna Fundamental Investments's RCKT Position: Q1 2026 in Review

Susquehanna Fundamental Investments sold out of Rocket Pharmaceuticals (RCKT) in Q1 2026, closing a stake of 50,970 shares — an estimated $179K sold.

Susquehanna Fundamental Investments first reported a position in RCKT in Q1 2021 and held it in 5 quarters. The position peaked at $1.37M in Q1 2025. 199 funds tracked by Wall St. Rank hold RCKT as of Q1 2026.

Susquehanna Fundamental Investments reported no remaining Rocket Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
Susquehanna Fundamental Investments sold 50,970 Rocket Pharmaceuticals shares in Q1 2026, an estimated $179K.
Susquehanna Fundamental Investments first reported a position in Rocket Pharmaceuticals in Q1 2021 and held it in 5 quarters.
Susquehanna Fundamental Investments's Rocket Pharmaceuticals position peaked at $1.37M in Q1 2025.
199 funds tracked by Wall St. Rank held Rocket Pharmaceuticals as of Q1 2026.

Based on Susquehanna Fundamental Investments's 13F filing for Q1 2026, filed 15 May 2026.